<h4>Objective</h4>The safety results of different recommended doses of sodium-glucose cotransporter 2 inhibitors (SGLT-2i) for patients with type 2 diabetes mellitus (T2DM) remain uncertain. This evidence concerns the gene SLC5A2 and diabetes mellitus.